| Issue |
Section |
Title |
File |
| Vol 82, No 2 (2010) |
Editorial |
USE of allogeneic mesenchymal stem cells in the treatment of intestinal inflammatory diseases |
|
| Vol 90, No 3 (2018) |
Editorial |
Stem Cell Therapy for Perianal Crohn’s Disease |
(Rus)
|
| Vol 90, No 6 (2018) |
Editorial |
Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice |
(Rus)
|
| Vol 90, No 2 (2018) |
Editorial |
Personalized medicine in the treatment of inflammatory bowel diseases |
(Rus)
|
| Vol 90, No 2 (2018) |
Editorial |
Mesenchymal stromal cells of bone marrow and azathioprine in Crohn's disease therapy |
(Rus)
|
| Vol 90, No 12 (2018) |
Editorial |
Adherence to therapy of patients with inflammatory bowel diseases |
(Rus)
|
| Vol 90, No 11 (2018) |
Editorial |
Clostridium difficile in inflammatory bowel disease |
(Rus)
|
| Vol 91, No 2 (2019) |
Editorial |
Important problems in the diagnosis and treatment of primary sclerosing cholangitis (based on the Russian consensus on diagnosis and treatment autoimmune hepatitis. Moscow, 2018) |
(Rus)
|
| Vol 90, No 12 (2018) |
Editorial |
Biomarkers of inflammatory bowel disease activity |
(Rus)
|
| Vol 91, No 2 (2019) |
Editorial |
Celiac disease associated with ulcerative colitis |
(Rus)
|
| Vol 91, No 4 (2019) |
Editorial |
O.V. Knyazev, A.V. Kagramanova, I.A. Korneeva, K.K. Noskova, S.V. Belousov, A.I. Parfenov |
(Rus)
|
| Vol 91, No 8 (2019) |
Editorial |
Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation |
(Rus)
|
| Vol 92, No 2 (2020) |
Editorial |
Systemic manifestations of inflammatory bowel diseases |
(Rus)
|
| Vol 92, No 2 (2020) |
Original articles |
Pharmacological and clinical feature of rebamipide: new therapeutic targets |
(Rus)
|
| Vol 93, No 2 (2021) |
Original articles |
Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars |
(Rus)
|
| Vol 93, No 8 (2021) |
Reviews |
Is histological remission of ulcerative colitis achievable? |
(Rus)
|
| Vol 93, No 12 (2021) |
Editorial |
Low adherence to treatment is a weak link in the problems of ulcerative colitis |
(Rus)
|
| Vol 93, No 12 (2021) |
Original articles |
Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy |
(Rus)
|
| Vol 93, No 12 (2021) |
History of medicine |
Ulcerative colitis. To the 180th anniversary of the description by Karl Rokytansky |
(Rus)
|
| Vol 94, No 2 (2022) |
Original articles |
Frequency and risk factors for thromboembolic complications in patients with inflammatory bowel diseases |
(Rus)
|
| Vol 95, No 2 (2023) |
History of medicine |
Crohn disease: before and after 1932 year |
(Rus)
|
| Vol 95, No 11 (2023) |
Clinical notes |
Tuberculosis infection in patients with inflammatory bowel diseases. Clinacal cases |
(Rus)
|
| Vol 96, No 2 (2024): Issues of gastroenterology |
Clinical notes |
Ulcerative colitis and autoimmune uveitis. Case report |
(Rus)
|
| Vol 97, No 2 (2025): Вопросы гастроэнтерологии |
History of medicine |
Evolution of enterology as a science |
(Rus)
|
| Vol 97, No 2 (2025): Вопросы гастроэнтерологии |
Original articles |
Prevention of venous thromboembolic complications in patients with ulcerative colitis |
(Rus)
|
| Vol 97, No 2 (2025): Вопросы гастроэнтерологии |
Original articles |
Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitis |
(Rus)
|
| Vol 97, No 2 (2025): Вопросы гастроэнтерологии |
Consensuns |
Russian Cross-disciplinary Consensus on the diagnosis and treatment of spondyloarthritis associated with inflammatory bowel diseases |
(Rus)
|
